May 17, 2024
IQ-AI Ltd
("IQ-AI" or the
"Company")
Imaging Biometrics Software
Enhances Clinical Decision-Making at Insel Gruppe
AG
Imaging Biometrics (IB), Elm Grove,
WI, a wholly owned subsidiary of IQ-AI Ltd (LSE: IQAI), announces
the successful deployment of its state-of-the-art software at Insel
Gruppe AG in Bern, Switzerland. This installation was facilitated
through Bayer's Calantic™ platform on which IB's exclusive
algorithms are made available under a partnership
agreement.
Clinicians at Insel Gruppe AG are
now equipped with IB's quantitative imaging solutions, renowned for
their precision and reliability in aiding critical clinical
decisions. The technology is especially beneficial to
neuroradiologists, oncologists, and surgeons, providing them with
enhanced capabilities to determine the best course of action for
their patients swiftly and effectively.
Dr. Arsany Hakim, MD, Head of Brain
Tumor Imaging at the Institute of Diagnostic and Interventional
Neuroradiology, stated, "The incorporation of IB's software into
our clinical workflow marks a significant step towards the
standardization of advanced imaging, enhancing both clinical
workflow and patient care. We are eager to utilize the capabilities
offered by IB's solutions in our team to enhance lesion detection
and to advance patient monitoring process, ultimately to improve
patient outcomes".
Echoing this sentiment, Prof. Roland
Wiest, MD, Deputy Director of Neuroradiology at Insel Gruppe AG,
commented, "The adoption of
IB's advanced imaging is expected to be a game-changer
in our patient care strategy. We foresee an immediate enhancement
in our ability to tailor treatments to individual
needs."
"We are thrilled to witness the
integration of our Calantic partner, Imaging Biometrics, into the
everyday clinical workflow at Insel Gruppe AG, where it stands
poised to provide invaluable support to radiologists and their
teams," said Lucia Fernandez Lopez, Head of Digital Solutions
Business EMEA, Radiology at Bayer. "With its precise imaging tools,
the platform empowers enhanced diagnostics and treatment planning,
fostering efficiency in image analysis while offering advanced
capabilities for biomarker quantification. These advantages
collectively elevate clinical decision-making, ultimately
optimizing patient care within the radiology practice."
Michael Schmainda, CEO of Imaging
Biometrics, reflected on the significance of this
collaboration: "The
installation at Insel Gruppe AG allows them full access to our
comprehensive suite of applications. We are excited about this
collaboration and are committed to supporting Insel Gruppe AG as
they set new standards in patient care."
--ENDS-
The Directors of the Company accept
responsibility for the contents of this announcement.
For further information, please
contact:
IQ-AI Ltd
Trevor Brown/Vinod Kaushal/Brett
Skelly/Michael Schmainda
Tel: 020 7469 0930
|
Peterhouse Capital Limited (Financial Adviser and Broker)
Lucy Williams/Heena
Karani
Tel: 020 7220 9797
|
About Insel Gruppe AG
Insel Gruppe AG, one of the
longest-running university hospitals in Europe, was founded in 1354
and has since become a leading medical institution in Europe,
playing a pivotal role in medical education and training. Housing 8
MRI scanners and conducting over 23,000 MRI scans annually, the
University Institute of Diagnostic and Interventional
Neuroradiology at Insel Gruppe AG stands as the largest
neuroradiology department in Switzerland. The department is
equipped with state-of-the-art technology, including high-field
MRI, and is nationally and internationally recognized for its
clinical excellence and contributions to the field.
In collaboration with the departments
of Neurosurgery, Clinical Oncology, Radiation Therapy, Pathology,
and Neurology, the Brain Tumor Center in Bern is renowned across
Switzerland. It offers advanced diagnostic services and
personalized patient management.
About Imaging Biometrics® LLC
IB is a wholly owned subsidiary of IQ-AI Limited,
(LON: IQAI), and focuses on delivering quantitative imaging
platforms and therapeutics that transform how clinicians diagnose
and treat patients more efficiently and effectively. For more
information about Imaging Biometrics, visit the company's website
at www.imagingbiometrics.com. Follow
IB on Twitter, @IQAI_IB.